CClinicalTrials.gg
Sign In
CompletedNCT05095155Updated Mar 14, 2023

Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Kazakh Nationality

An observational study in B Cell Leukemia and Lymphoma, sponsored by Asfendiyarov Kazakh National Medical University. Completed at 1 site in Kazakhstan. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-03-14.

Sponsored by Asfendiyarov Kazakh National Medical University · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
400
Ages
0 Years to 18 Years
Sex
All
01

Study summary

To search for a genetic marker of B-cell leukemias and lymphomas in children of Kazakh nationality, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with B-cell leukemias and lymphomas in children of Kazakh nationality and normal control will be performed.

02

Conditions studied

  • B Cell Leukemia
  • Lymphoma

Keywords

  • SNP
03

In context

Lymphoma

5,579 studies on the registry are indexed under Lymphoma; 825 are open to participants now.

This study's enrollment of 400 is above the median of 136 across 625 observational studies indexed under Lymphoma.

Browse Lymphoma studies →

Lead sponsor

Asfendiyarov Kazakh National Medical University is the lead sponsor of 19 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Children of the Kazakh population

Inclusion criteria

  • ethnicity - Kazakhs in at least three generations
  • active disease or a history of B-line ALL or B-NHL, established on the basis of morphological, cytochemical, immunophenotypic or immunohistochemical research methods with confirmation of the fact of the disease in medical documentation
  • Signed voluntary informed consent of the legal representative to participate in the project

Exclusion criteria

Exclusion Criteria:

  • Children suffering from other types of malignant neoplasms
  • Children with B-linear leukemia and lymphomas with concomitant specified genetic and chromosomal diseases
  • Children of non-Kazakh nationality
  • Absence of signed informed consent or informed refusal of the legal representative to participate in the study before starting therapy
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
400 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Experimental group:

    children with B-cell leukemia and lymphoma of Kazakhstani nationality

    Genetic: SNP analysis of the DNA

  • Control group

    children without B-cell leukemia and lymphoma of Kazakhstani nationality

    Genetic: SNP analysis of the DNA

Interventions

  • GeneticSNP analysis of the DNA

    SNP analysis of the DNA obtained from peripheral blood sample

    Also known as: SNP analysis of the DNA obtained from peripheral blood sample

06

What researchers measure

Primary outcomes

  1. Associated with B-cell lymphoma and B-cell acute lymphoblastic leukemia

    Genotype frequency of SNP in the study genes of participants and control participants.

    Time frame: 1 year

07

Study locations

1 site
  • Scientific Center of Pediatrics and Pediatric Surgery
    Almaty, Kazakhstan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05095155
Lead sponsor
Asfendiyarov Kazakh National Medical University
Responsible party
Ildar Fakhradiyev (Head of the Laboratory of Experimental Medicine, Asfendiyarov Kazakh National Medical University) — Principal investigator
First posted
Oct 27, 2021
Start date
Apr 1, 2022
Primary completion
Jan 20, 2023
Completion
Jan 20, 2023
Last update
Mar 14, 2023

Study contacts

Riza Boranbayeva, PhD
principal investigator · JSC "Scientific Center of Pediatrics and Pediatric Surgery"

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lymphoma→

Other studies from this sponsor

Asfendiyarov Kazakh National Medical University

Start the discussion